Overview A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor Status: Terminated Trial end date: 2021-04-27 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the safety and efficacy of Surufatinib plus Sintilimab in Patients with Advanced Solid Tumor Phase: Phase 1 Details Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.